Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 12, 2012 - Issue 12
Submit an article Journal homepage
191
Views
10
CrossRef citations to date
0
Altmetric
Theme: Kidney Cancer - Review

Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives

Marc-Olivier Timsit Department of Urology, Hôpital Européen Georges Pompidou and Hôpital Necker, AP-HP, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France; Inserm U765, Paris, France; Department of Urology, Hôpital Européen Georges Pompidou and Hôpital Necker, AP-HP, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France; Inserm U765, Paris, France
,
Laurence Albiges Medical Oncology, InstitutGustaveRoussy, Villejuif, France; Université Paris Sud, Paris, France; Medical Oncology, InstitutGustaveRoussy, Villejuif, France; Université Paris Sud, Paris, France
,
Arnaud Méjean Department of Urology, Hôpital Européen Georges Pompidou and Hôpital Necker, AP-HP, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France; Department of Urology, Hôpital Européen Georges Pompidou and Hôpital Necker, AP-HP, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France
&
Bernard Escudier Medical Oncology, InstitutGustaveRoussy, Villejuif, France; Medical Oncology, InstitutGustaveRoussy, Villejuif, France. [email protected]
Pages 1559-1569 | Published online: 10 Jan 2014

References

  • Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res. 13(2 Pt 2), s697–s702 (2007).
  • Kong X, Moran MS, Zhang N, Hafty B, Yang Q. Meta-analysis confirms achieving pathological complete response ater neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur. J. Cancer 47(14), 2084–2090 (2011).
  • Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br. J. Surg. 99(7), 918–928 (2012).
  • Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115–124 (2007).
  • Cost NG, Delacroix SE Jr, Sleeper JP et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur. Urol. 59(6), 912–918 (2011).
  • Cowey CL, Amin C, Pruthi RS et al. Neoadjuvant clinical trial with soraenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol. 28(9), 1502–1507 (2010).
  • Jonasch E, Wood CG, Matin SF et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(25), 4076–4081 (2009).
  • Abel EJ, Culp SH, Tannir NM et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur. Urol. 59(1), 10–15 (2011).
  • Powles T, Kayani I, Blank C et al. The saety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann. Oncol. 22(5), 1041–1047 (2011).
  • Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061–1068 (2010).
  • Motzer RJ, Agarwal N, Beard C et al.; National Comprehensive Cancer Network. Testicular cancer. J. Natl. Compr. Canc. Netw. 10(4), 502–535 (2012).
  • Rini B, Grünwald V, Fishman MN et al. Axitinib for first-line metastatic renal cell carcinoma (mRCC): overall efficacy and pharmacokinetic (PK) analyses from a randomized Phase II study. J. Clin. Oncol. 30, Abstract 4503 (2012).
  • Rodríguez Faba O, Breda A, Rosales A et al. Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma. Eur. Urol. 58(2), 307–310 (2010).
  • Karam JA, Rini BI, Varella L et al. Metastasectomy ater targeted therapy in patients with advanced renal cell carcinoma. J. Urol. 185(2), 439–444 (2011).
  • Albiges L, Oudard S, Negrier S et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J. Clin. Oncol. 30(5), 482–487 (2012).
  • Powles T, Blank C, Chowdhury S et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur. Urol. 60(3), 448–454 (2011).
  • Chapin BF, Delacroix SE Jr, Culp SH et al. Saety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur. Urol. 60(5), 964–971 (2011).
  • van der Veldt AA, Meijerink MR, van den Eertwegh AJ et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin. Cancer Res. 14(8), 2431–2436 (2008).
  • Patard JJ, Thuret R, Rafi A, Laguerre B, Bensalah K, Culine S. Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur. Urol. 55(1), 237–239; quiz 239 (2009).
  • Shuch B, Riggs SB, LaRochelle JC et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 102(6), 692–696 (2008).
  • Karakiewicz PI, Suardi N, Jeldres C et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur. Urol. 53(4), 845–848 (2008).
  • Bex A, van der Veldt AA, Blank C et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J. Urol. 27(4), 533–539 (2009).
  • Thomas AA, Rini BI, Lane BR et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181(2), 518–523; discussion 523 (2009).
  • Lambert EH, Pierorazio PM, Shabsigh A, Olsson CA, Benson MC, McKiernan JM. Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. Urology 69(6), 1054–1058 (2007).
  • Klatte T, Pantuck AJ, Riggs SB et al. Prognostic factors for renal cell carcinoma with tumor thrombus extension. J. Urol. 178(4 Pt 1), 1189–1195; discussion 1195 (2007).
  • Karnes RJ, Blute ML. Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus. Nat. Clin. Pract. Urol. 5(6), 329–339 (2008).
  • Shuch B, Crispen PL, Leibovich BC et al. Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality? BJU Int. 107(5), 724–728 (2011).
  • Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 94(1), 33–41 (2004).
  • Di Silverio F, Sciarra A, Parente U et al. Neoadjuvant therapy with soraenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol. Int. 80(4), 451–453 (2008).
  • Harshman LC, Srinivas S, Kamaya A, Chung BI. Laparoscopic radical nephrectomy ater shrinkage of a caval tumor thrombus with sunitinib. Nat. Rev. Urol. 6(6), 338–343 (2009).
  • Robert G, Gabbay G, Bram R et al. Case study of the month. Complete histologic remission ater sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur. Urol. 55(6), 1477–1480 (2009).
  • Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol. 49(4), 520–523 (2010).
  • Huang WC, Levey AS, Serio AM et al. Chronic kidney disease ater nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 7(9), 735–740 (2006).
  • Thompson RH, Boorjian SA, Lohse CM et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J. Urol. 179(2), 468–471; discussion 472 (2008).
  • Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J. Urol. 163(3), 730–736 (2000).
  • Patard JJ, Shvarts O, Lam JS et al. Saety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J. Urol. 171(6 Pt 1), 2181–2185, quiz 2435 (2004).
  • Weight CJ, Larson BT, Fergany a et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J. Urol. 183(4), 1317–1323 (2010).
  • Miller DC, Schonlau M, Litwin MS, Lai J, Saigal CS; Urologic Diseases in America Project. Renal and cardiovascular morbidity ater partial or radical nephrectomy. Cancer 112(3), 511–520 (2008).
  • Van Poppel H, Da Pozzo L, Albrecht W et al. A prospective, randomised EORTC intergroup Phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur. Urol. 59(4), 543–552 (2011).
  • Margulis V, Tamboli P, Jacobsohn KM, Swanson DA, Wood CG. Oncological efficacy and saety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. BJU Int. 100(6), 1235–1239 (2007).
  • Thomas AA, Rini BI, Stephenson AJ et al. Surgical resection of renal cell carcinoma ater targeted therapy. J. Urol. 182(3), 881–886 (2009).
  • Gorin MA, Garcia-Roig M, Shirodkar SP, Gonzalez J, Ciancio G. Modified surgical technique for the management of renal cell carcinoma with level I or II tumor thrombus. Urology 79(2), 478–481 (2012).
  • Krajewski KM, Guo M, Van den Abbeele AD et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur. Urol. 59(5), 856–862 (2011).
  • Hellenthal NJ, Underwood W, Penetrante R et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J. Urol. 184(3), 859–864 (2010).
  • Bex A, Jonasch E, Kirkali Z et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur. Urol. 58(6), 819–828 (2010).
  • Di Lorenzo G, Porta C, Bellmunt J et al. Toxicities of targeted therapy and their management in kidney cancer. Eur. Urol. 59(4), 526–540 (2011).
  • Bessede T, Pignot G, Patard JJ. Saety issues and rationale for neoadjuvant approaches in renal cell carcinoma. Eur. Urol. 60(5), 972–974 (2011).
  • Margulis V, Matin SF, Tannir N et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 180(1), 94–98 (2008).
  • Howdieshell TR, Callaway D, Webb WL et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J. Surg. Res. 96(2), 173–182 (2001).
  • Li WW, Talcott KE, Zhai AW, Kruger EA, Li VW. The role of therapeutic angiogenesis in tissue repair and regeneration. Adv. Skin Wound Care 18(9), 491–500; quiz 501 (2005).
  • Mills RE, Taylor KR, Podshivalova K, McKay DB, Jameson JM. Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated mice. J. Immunol. 181(6), 3974–3983 (2008).
  • Valente JF, Hricik D, Weigel K et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am. J. Transplant. 3(9), 1128–1134 (2003).
  • Troppmann C, Pierce JL, Gandhi MM, Gallay BJ, McVicar JP, Perez RV. Higher surgical wound complication rates with sirolimus immunosuppression ater kidney transplantation: a matched-pair pilot study. Transplantation 76(2), 426–429 (2003).
  • Srivastava A, Muruganandham K, Vinodh PB et al. Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolatemofetil vs. m-TOR inhibitors. Int. Urol. Nephrol. 42(2), 279–284 (2010).
  • Flechner SM, Zhou L, Derweesh I et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 76(12), 1729–1734 (2003).
  • Kuppahally S, Al-Khaldi A, Weisshaar D et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am. J. Transplant. 6(5 Pt 1), 986–992 (2006).
  • Albano L, Berthoux F, Moal MC et al.; RAD A2420 Study Group. Incidence of delayed grat function and wound healing complications ater deceased-donor kidney transplantation is not afected by de novo everolimus. Transplantation 88(1), 69–76 (2009).
  • Burgos FJ, Pascual J, Quicios C et al. Post-kidney transplant surgical complications under new immunosuppressive regimens. Transplant. Proc. 38(8), 2445–2447 (2006).
  • Kesmodel SB, Ellis LM, Lin E et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J. Clin. Oncol. 26(32), 5254–5260 (2008).
  • Raut CP, Wang Q, Manola J et al. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann. Surg. Oncol. 17(2), 407–415 (2010).
  • Tobert CM, Uzzo RG, Wood CG, Lane BR. Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the society of urologic oncology. Urol. Oncol. doi:10.1016/j.urolonc.2011.12.014 (2012) (Epub ahead of print).
  • Silberstein JL, Millard F, Mehrazin R et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 106(9), 1270–1276 (2010).
  • Seidel C, Fenner M, Merseburger AS et al. Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients. World. J. Urol. 29(3), 355–360 (2011).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.